Vaccination with CIITA-driven MHC-II-expressing tumor cells has a potential to induce a potent TH immune response through a diverse antigenic repertoire and to transform the tumor microenvironment from a noninflamed to an inflamed phenotype (20). The gene discussed is CIITA; the disease is neoplasm.